中枢神经系统治疗市场规模、份额、成长分析，按疾病类型、按药物类型、按药物类别、按分销管道、按地区 - 行业预测，2025 年至 2032 年

预计 2023 年全球中枢神经系统治疗市场规模将达到 1,282.9 亿美元，并从 2024 年的 1,363.7 亿美元成长到 2032 年的 2,223.3 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.3%。

世界上越来越思觉失调症和阿兹海默症）的发病率激增。这一趋势要求采取多学科治疗方法，包括神经外科医生、神经科和物理治疗师，促进合作，为患者照护。神经科学的不断进步正在推动创新治疗方法的发展，包括手术技术、基因治疗和神经影像技术。根据世界卫生组织 (WHO) 统计，全球有超过 10 亿人受到影响，製药公司正在透过投资新的中枢神经系统药物来满足尚未满足的重大医疗需求。此外，学名药的普及有望改善治疗机会，特别是在中低收入国家，从而促进中枢神经系统药物市场的成长和竞争的加剧。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 宏观经济指标
• 价值链分析
• 定价分析

中枢神经系统治疗市场规模（依疾病类型）

• 市场概况
• 神经血管疾病
  • 出血性中风
  • 缺血性中风
  • 其他的
• 神经退化性疾病
  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 其他的
• 心理健康
  • 癫痫
  • 情绪障碍
  • 焦虑症
  • 其他的
• 感染疾病
  • 脑膜炎
  • 脑炎
  • 其他的
• 其他的

中枢神经系统治疗市场规模（依药物类型）

• 市场概况
• 生物製药
• 非生技药品

中枢神经系统治疗市场规模（依药物类别）

• 市场概况
• 免疫调节药物
• 干扰素
• 脱羧酶抑制剂
• 促效剂
• 抗忧郁症
• 止痛药
• 其他的

中枢神经系统治疗市场规模（按分销管道）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

中枢神经系统治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Biogen Inc.（United States）
• Johnson & Johnson（United States）
• Novartis AG（Switzerland）
• UCB SA（Belgium）
• Takeda Pharmaceutical Company Ltd.（Japan）
• Pfizer Inc.（United States）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Eli Lilly and Company（United States）
• Otsuka Holdings Co., Ltd.（Japan）
• Lundbeck A/S（Denmark）
• GlaxoSmithKline plc（GSK）（United Kingdom）
• AstraZeneca plc（United Kingdom）
• Merck & Co., Inc.（United States）
• Bristol-Myers Squibb Company（United States）
• Amgen Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（United States）
• Allergan plc（Ireland）
• Shionogi & Co., Ltd.（Japan）

结论和建议

Global Central Nervous System Treatment Market size was valued at USD 128.29 billion in 2023 and is poised to grow from USD 136.37 billion in 2024 to USD 222.33 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

The global rise in sedentary and hectic lifestyles has resulted in a surge of chronic and central nervous system (CNS) disorders, such as schizophrenia and Alzheimer's disease. This trend has necessitated a multidisciplinary treatment approach involving neurosurgeons, neurologists, and physical therapists, fostering collaboration for comprehensive patient care. Ongoing advancements in neuroscience are driving the development of innovative treatments, including surgical techniques, gene therapies, and neuroimaging technologies. As the World Health Organization reports over 1 billion affected individuals worldwide, pharmaceutical companies are responding by investing in new CNS therapies to address significant unmet medical needs. Additionally, the availability of generic medications is enhancing treatment access, particularly in low- and middle-income countries, promising market growth and increased competition in CNS therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Treatment Market Segmental Analysis

Global Central Nervous System Treatment Market is segmented by Disease Type, Drug Type, Drug Class, Distribution Channel and region. Based on Disease Type, the market is segmented into Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, Infectious Diseases and Others. Based on Drug Type, the market is segmented into Biologics and Non-biologics. Based on Drug Class, the market is segmented into Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Antidepressants, Analgesics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Treatment Market

The Global Central Nervous System Treatment market is being propelled by a notable increase in the incidence of mental health disorders and significant advancements in pipeline research. The rising global prevalence of neurological conditions such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease is a major factor in driving market expansion. Additionally, the aging population in many regions is contributing to the surge in Alzheimer's cases; the Alzheimer's Association reports over five million individuals currently affected, with projections reaching 14 million by 2050. Furthermore, the potential launch of new treatments for these conditions is expected to enhance healthcare access in developing nations, exemplified by Corbus Pharmaceuticals' ongoing Phase 3 clinical trial of Lenabasum for diffuse cutaneous systemic sclerosis. This combination of rising disease prevalence and innovative treatment options creates a robust foundation for growth in the sector.

Restraints in the Global Central Nervous System Treatment Market

The Global Central Nervous System Treatment market faces significant restraints primarily due to the high costs associated with drug development and complex regulatory requirements. Investment in research and development for therapies targeting CNS disorders is notably higher compared to other therapeutic areas. The specialized nature of CNS treatments mandates a high level of precision, but there is a scarcity of qualified medical professionals to conduct such work. Additionally, the lengthy drug approval process, which can span several years, complicates the timeline for bringing CNS drugs to market. Insufficient understanding of neuroscience may hinder timely approvals and delay the introduction of effective treatments for CNS disorders.

Market Trends of the Global Central Nervous System Treatment Market

The Global Central Nervous System (CNS) Treatment market is experiencing robust growth, driven by increasing investments in neuroscience research, drug development, and innovative therapeutic solutions. Rising incidences of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis are propelling demand for more effective treatments. Additionally, advancements in technology, including neuroimaging and biomarker discovery, are providing new avenues for targeted therapies. Key market players are collaborating with biotech firms and academia to accelerate the development of personalized medicine. The market is also witnessing a surge in funding from governmental and private sectors aimed at enhancing CNS treatment options, forecasting significant expansion through the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Central Nervous System Treatment Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Neurovascular Diseases
  • Hemorrhagic Stroke
  • Ischemic Stroke
  • Others
• Neurodegenerative Diseases
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Others
• Mental Health
  • Epilepsy
  • Mood Disorders
  • Anxiety Disorders
  • Others
• Infectious Diseases
  • Meningitis
  • Encephalitis
  • Others
• Others

Global Central Nervous System Treatment Market Size by Drug Type & CAGR (2025-2032)

• Market Overview
• Biologics
• Non-biologics

Global Central Nervous System Treatment Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulatory Drugs
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Antidepressants
• Analgesics
• Others

Global Central Nervous System Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Central Nervous System Treatment Market Size & CAGR (2025-2032)

• North America (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations